Caenorhabditis elegans-based enterococcus faecalis SI-FC-01 anti-aging and neuroprotective effects

Abstract

The invention discloses an anti-aging and neuroprotective effect of enterococcus faecalis SI-FC-01 based on caenorhabditis elegans, and belongs to the technical field of microbial application. The enterococcus faecalis SI-FC-01 separated from human intestinal flora is preserved in the China Center for Type Culture Collection (Wuhan University), and the preservation number of the enterococcus faecalis SI-FC-01 is CCTCC NO: M 2024091. The invention has the following beneficial effects: the study shows that the strain as a food supplement has good anti-aging, life-prolonging and neuroprotective effects on caenorhabditis elegans, is safe and free of toxic and side effects on caenorhabditis elegans, and can be used for preparing or developing anti-aging, neuroprotective and antibacterial products so as to be applied to delaying senescence, prolonging life and protecting neurological diseases. The strain has good practical application value, and an excellent basic strain is provided for further research and development of microbial anti-aging products.

Description

Technical Field

[0001] The present invention relates to the field of microbial application technology, and specifically to the anti-aging and neuroprotective effects of Enterococcus faecalis SI-FC-01 based on Caenorhabditis elegans. Background Art

[0002] Aging has long been a topic of concern. The factors influencing aging and lifespan are complex, primarily linked to genetics, the environment, and lifestyle factors. They represent a complex multifactorial phenomenon, manifesting as decreased tissue and cellular function and an increased risk of many so-called age-related diseases. Delaying the aging process can slow the onset and progression of age-related diseases and disabilities in the elderly. Therefore, aging has always been a long-standing area of ​​research for scientists, and research on the mechanisms of aging and its delay has attracted significant attention from numerous scholars. There is an urgent need to explore known and novel compounds that can extend human lifespan by intervening in aging pathways.

[0003] At the same time, exposure to environmental neurotoxins (such as heavy metals and persistent organic pollutants) caused by industrialization has a synergistic effect with aging. This "aging + environmental pollution" double whammy leads to irreversible neuronal damage and decreased synaptic plasticity through mechanisms such as oxidative stress, protein homeostasis imbalance, and mitochondrial dysfunction, ultimately triggering neurodegenerative diseases. Intervention for neurological diseases has also become a key research topic in the field of aging.

[0004] Natural products are small molecules naturally produced from a variety of sources, including animal and plant extracts, insects, marine organisms, and microorganisms. Currently, many clinical drugs are derived from synthetic compounds. Natural products are secondary metabolites with biologically relevant chemical spaces and preferred ligand-binding motifs. They are not only biologically active but also highly bioavailable, making them suitable for functional and phenotypic assays. Among the many natural products, microbial natural products hold great promise for development and are an important source of pharmaceuticals or health supplements. Between 1981 and 2019, approximately 1,881 therapeutically effective small molecule drugs were marketed, 46% of which were derived from natural products or derivatives. Of the 160,000 natural products with known structures, approximately 50% are derived from microorganisms. Numerous studies have demonstrated that microorganisms have effective therapeutic effects in treating neurodegenerative diseases, cardiovascular disease, type 2 diabetes, and age-related diseases such as arthritis.

[0005] Caenorhabditis elegans is a common, small soil nematode with a simple anatomical structure, but its muscles, nervous system, gastrointestinal tract, gonads, and other tissues and organs are similar to those of higher animals. In addition, the nematode genome is homologous to that of humans, its signaling pathways are similar to those of humans, and it exhibits significant age-related physiological changes. Because early drug screening requires relatively small space, low cost, and time, the relatively short lifespan of C. elegans ensures that this organism can be used for high-throughput screening of anti-aging drugs.

[0006] Chinese patent application publication number CN113122466A discloses Enterococcus faecalis. This strain is a novel probiotic that can withstand the acidic environment of gastric juice and the bile salt environment in the intestines. It has strong acid and bile salt resistance. However, this strain does not possess anti-aging or neuroprotective properties, and thus needs further improvement. Summary of the Invention

[0007] The technical problem to be solved by the present invention is how to propose a new strain of Enterococcus faecalis and its application in anti-aging and neuroprotection.

[0008] The present invention solves the above technical problems through the following technical means:

[0009] The first aspect of the present invention provides an Enterococcus faecalis SI-FC-01 having anti-aging and neuroprotective effects, with a deposit number of CCTCC NO: M 2024091.

[0010] The strain was deposited in the China Center for Type Culture Collection (Wuhan University) on January 12, 2024, and the preservation name is Enterococcus faecalis SI-FC-01.

[0011] The second aspect of the present invention provides the use of the above-mentioned Enterococcus faecalis SI-FC-01 in the preparation of anti-aging and / or neuroprotective drugs in Caenorhabditis elegans.

[0012] A third aspect of the present invention provides a bacterial agent comprising the aforementioned Enterococcus faecalis SI-FC-01 or its fermentation supernatant or lysate.

[0013] The fourth aspect of the present invention provides any of the following applications of the above-mentioned bacterial agent:

[0014] (1) Application in the preparation of anti-aging products;

[0015] (2) Application in the preparation of products with extended lifespan;

[0016] (3) Application in the preparation of antioxidant products;

[0017] (4) Application in the preparation of products that reduce lipofuscin content;

[0018] (5) Application in the preparation of neuroprotective products;

[0019] (6) Application in the preparation of antibacterial products.

[0020] Preferably, in (1) to (5), the product is a health product, a medicine, a feed or an additive thereof.

[0021] Preferably, in (1) to (5), the product is in the form of liquid, jelly, stick, powder, tablet, granule or capsule.

[0022] Preferably, the product is a medicine, which further comprises a pharmaceutically acceptable carrier.

[0023] Preferably, the pharmaceutically acceptable carrier is selected from one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.

[0024] Preferably, the drug is prepared into a pharmaceutically acceptable dosage form.

[0025] A fifth aspect of the present invention provides a method for delaying aging and / or neuroprotection in Caenorhabditis elegans, comprising the following steps:

[0026] The Enterococcus faecalis SI-FC-01 bacterial solution is added to the culture medium as a food supplement for Caenorhabditis elegans.

[0027] The beneficial effects of the present invention are:

[0028] 1. The Enterococcus faecalis SI-FC-01 provided by the present invention is isolated from human intestinal microorganisms. Traditional biological identification and molecular biological identification show that the strain belongs to the genus Enterococcus faecalis. The SI-FC-01 strain is light gray, has neat edges, a smooth, moist, opaque surface, and round protrusions, and is a Gram-positive bacterium.

[0029] 2. Research conducted in this study demonstrates that using the Enterococcus faecalis SI-FC-01 strain as a food supplement for Caenorhabditis elegans can extend lifespan, increase body length, reduce gonadal cell apoptosis, and decrease lipofuscin content, thereby delaying aging. This strain can be used to aid in the preparation of anti-aging products, thereby alleviating aging and prolonging lifespan. It possesses excellent practical application value and provides an excellent foundational strain for the further research and development of anti-aging products. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is a colony morphology diagram of Enterococcus faecalis SI-FC-01 in Example 1 of the present invention.

[0031] Figure 2 This is a diagram showing the Gram staining results of Enterococcus faecalis SI-FC-01 in Example 1 of the present invention.

[0032] Figure 3 Graphs showing the anti-aging effects of Enterococcus faecalis SI-FC-01 as a food supplement on Caenorhabditis elegans in Example 2; A is a comparison of average lifespans; and B is a comparison of survival rates.

[0033] Figure 4 This figure shows the effect of Enterococcus faecalis SI-FC-01 as a food supplement on the body length and width of Caenorhabditis elegans in Example 3.

[0034] Figure 5 This figure shows the effect of Enterococcus faecalis SI-FC-01 as a food supplement on gonadal cell apoptosis in Caenorhabditis elegans in Example 3.

[0035] Figure 6 This figure shows the effect of Enterococcus faecalis SI-FC-01 as a food supplement on the movement of Caenorhabditis elegans in Example 3.

[0036] Figure 7 This figure shows the effect of Enterococcus faecalis SI-FC-01 as a food supplement on lipofuscin in Caenorhabditis elegans on day 8 in Example 4.

[0037] Figure 8 The results of the experiment on Enterococcus faecalis SI-FC-01 against the common G- Figure 2 shows the antagonistic effect of Escherichia coli on Bacillus sp.

[0038] Figure 9 The results of the experiment on Enterococcus faecalis SI-FC-01 against the common G + Antagonistic effect diagram of cocci, Staphylococcus aureus, Streptococcus tenacity and Enterococcus faecium.

[0039] Figure 10 This is a diagram showing the antagonistic effect of Enterococcus faecalis SI-FC-01 on Corynebacterium striatum in Example 1.

[0040] Figure 11 This is a diagram showing the antagonistic effect of Enterococcus faecalis SI-FC-01 against Listeria in Example 1.

[0041] Figure 12 This is a diagram showing the antagonistic effect of Enterococcus faecalis SI-FC-01 on Serratia marcescens in Example 1.

[0042] Figure 13 This figure shows the protective effect of Enterococcus faecalis SI-FC-01 on dopamine neurons under 5 levels of Mn pollution.

[0043] Figure 14 This figure shows the protective effect of Enterococcus faecalis SI-FC-01 on dopamine neurons under PFOS contamination in Example 5.

[0044] Figure 15 This figure shows the effect of Enterococcus faecalis SI-FC-01 on the Caenorhabditis elegans Parkinson's disease (PD) model in Example 5.

[0045] Figure 16 This figure shows the effect of Enterococcus faecalis SI-FC-01 on the Caenorhabditis elegans Huntington's disease (HD) model in Example 5.

[0046] Figure 17 This is a graph showing the hemolytic activity of Enterococcus faecalis SI-FC-01 in Example 2.

[0047] In the figures, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001. DETAILED DESCRIPTION

[0048] To make the objectives, technical solutions, and advantages of the embodiments of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts shall fall within the scope of protection of the present invention.

[0049] Unless otherwise specified, the test materials and reagents used in the following examples can be obtained from commercial sources.

[0050] If no specific techniques or conditions are specified in the examples, they can be carried out according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the quantitative tests in the following examples were repeated three times and the results were averaged.

[0051] The Nematode Growth Medium (NGM) used in the following examples has the following formula: 3 g sodium chloride, 2.5 g tryptone, 17 g agar powder, dilute to 1000 mL with distilled water, and sterilize by autoclaving at 121°C for 25 min. After the temperature drops to approximately 60°C, aseptically add 25 mL of 1 mol / L potassium phosphate buffer, 1 mL of 1 mol / L CaCl2 solution, 1 mL of 1 mol / L MgSO4 solution, and 1 mL of 5 mg / mL cholesterol solution (95% ethanol), shake well, and pour onto a plate.

[0052] Escherichia coli OP50: purchased from Caenorhabditis Genetics Center (CGC).

[0053] Example 1:

[0054] Isolation, Screening and Identification of Enterococcus faecalis SI-FC-01

[0055] The strain was discovered on May 16, 2022 in Laboratory 306, South Building, Comprehensive Laboratory Building, Hefei Institutes of Physical Science, Chinese Academy of Sciences. After systematic screening of healthy human intestinal microbial flora, a strain capable of inhibiting the growth of Staphylococcus aureus was found. The strain was streaked and purified on blood agar plates. From a morphological point of view, the colony morphology of the strain is light gray, with neat edges, smooth, moist, opaque surface, and round protrusions (such as Figure 1 Its Gram staining is blue-purple and the single cells are spherical, indicating that the strain is a Gram-positive bacterium. (As shown in Figure 2 shown)

[0056] The strain was preliminarily identified as Enterococcus faecalis using Bruker's matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF MS) and MALDI Biotyper 3.1 software, with a score of 2.420 (e.g. Figure 3 16S rRNA gene amplification was performed using bacterial universal primers (27F / 1492R). The gene sequence obtained after PCR product testing (GenBank Accession: OR064032) was compared and analyzed in NCBI. Using the above method, the strain numbered SI-FC-01 Enterococcus faecalis was obtained by screening.

[0057] The strain was deposited in the China Center for Type Culture Collection (Wuhan University) on January 12, 2024, with the preservation name Enterococcus faecalis SI-FC-01 and the preservation number CCTCC NO: M 2024091.

[0058] The Oxford cup plate antibacterial test showed that Enterococcus faecalis SI-FC-01 had antagonistic activity against Escherichia coli, Staphylococcus aureus, Streptococcus tenacus, Enterococcus faecium, Corynebacterium striata, Listeria monocytogenes, and Serratia marcescens. This indicates that Enterococcus faecalis SI-FC-01 secretes a substance with broad-spectrum antibacterial activity. (e.g. Figures 8-12 shown)

[0059] Safety Analysis of Enterococcus faecalis SI-FC-01:

[0060] This study combined hemolytic analysis and drug sensitivity testing to demonstrate the safety of Enterococcus faecalis SI-FC-01.

[0061] According to the standard clinical microbiology test method, in order to detect the hemolytic activity of Enterococcus faecalis SI-FC-01, we streak inoculated on Columbia blood plates and incubated them in a 37°C incubator for 24 hours to observe whether the culture medium showed hemolysis. Figure 17As shown, no transparent hemolytic ring or discolored zone appeared around the SI-FC-01 colonies, indicating that the strain lacks the ability to secrete hemolysin and the hemolytic activity test was negative. This finding confirms the biosafety of SI-FC-01 from the perspective of virulence factors and provides important experimental evidence for its application as a probiotic.

[0062] In addition, drug sensitivity test results showed that SI-FC-01 was sensitive to common antibiotics such as benzathine penicillin, ampicillin, erythromycin, and tetracycline, with no drug resistance detected (see Table 1 below).

[0063] Table 1: Sensitivity of SI-FC-01 to common antibiotics

[0064]

[0065] Example 2:

[0066] Application of Enterococcus faecalis SI-FC-01 in extending the lifespan of Caenorhabditis elegans

[0067] 1. Cultivation of Caenorhabditis elegans:

[0068] Wild-type nematodes N2 were placed on a plate coated with Escherichia coli OP50 (OD 600 =1) on solid nematode culture medium (NGM) as a standard food for nematodes, and cultured at 20°C in the dark.

[0069] 2. C. elegans synchronization steps:

[0070] Use M9 buffer to wash the nematodes that have developed into adults (3rd day) from the NGM and add them to a 1.5ml EP tube. After sedimentation and washing three times with M9 buffer, remove the supernatant, add lysis buffer (700μL M9 solution, 200μL 5% NaClO solution, 100μL 5M NaOH solution) and mix by inverting until about 2 / 3 of the worm body is lysed. Centrifuge (5600r / min) for 1 minute, remove the supernatant, and centrifuge twice with M9 buffer. Add the eggs to a 3.5mm culture dish containing 3mL M9 culture medium and incubate overnight at 20℃ to obtain synchronized nematodes.

[0071] 3. Determination of the Lifespan of Caenorhabditis elegans by Interference with Enterococcus faecalis SI-FC-01

[0072] Enterococcus faecalis SI-FC-01 and Escherichia coli OP50 were cultured in liquid LB medium at 37°C for 18 hours and diluted and concentrated to a concentration of OD 600=1, and then spread on NGM plates.

[0073] Test strain Enterococcus faecalis SI-FC-01 group: NGM plates containing Enterococcus faecalis SI-FC-01 and Escherichia coli OP50 bacterial suspension in a 1:1 ratio;

[0074] E. coli OP50 group: NGM plates containing only E. coli OP50 bacterial liquid.

[0075] Pick the synchronized L1 wild-type Caenorhabditis elegans N2 and grow them to the L4 stage on NGM plates coated with E. coli OP50 solution. Then pick 30 nematodes and culture them on NGM plates coated with the test strain Enterococcus faecalis SI-FC-01 (experimental group) or E. coli OP50 (control group) at 20°C. During the egg-laying period of Caenorhabditis elegans, pick the surviving nematodes and transfer them to new NGM plates every day to prevent newly hatched nematodes from affecting the experimental results. After the nematodes lay eggs, the surviving nematodes can be transferred to the corresponding fresh food NGM plates every 2 days. Starting from the 8th day, the death and survival status will be recorded. Nematodes that climb the wall, squeeze out organs, or lay eggs in the body will not be included in the statistics. The experiment will continue until all the nematodes die. The average lifespan (n is the total number of nematodes, x is the number of days each nematode survived) was calculated, and the maximum lifespan was recorded.

[0076] The results are as follows Figure 3 As shown, compared with the average lifespan (14.3d) and maximum lifespan (22d) of nematodes in the Escherichia coli OP50 group, the average lifespan of the Enterococcus faecalis SI-FC-01 group was extended by 30.06% (18.6d, p<0.05), and the maximum lifespan was extended by 5d (27d), indicating that the Enterococcus faecalis SI-FC-01 strain can prolong the lifespan of nematodes as a food supplement.

[0077] Example 3:

[0078] Effects of Enterococcus faecalis SI-FC-01 on the phenotype of Caenorhabditis elegans.

[0079] 1. Effects of Enterococcus faecalis SI-FC-01 on the body length and width of Caenorhabditis elegans.

[0080] Wild-type C. elegans N2 were synchronized and cultured on NGM plates containing OP50 or a 1:1 ratio of Enterococcus faecalis SI-FC-01 to E. coli OP50 at 20°C for 3 days. After developing into adults, the body length and width of the nematodes were measured. Figure 4 As shown, there was no significant change in the body length and width of nematodes supplemented with Enterococcus faecalis SI-FC-01 compared with the E. coli OP50 control group.

[0081] 2. Effect of Enterococcus faecalis SI-FC-01 on apoptosis of gonadal cells in Caenorhabditis elegans.

[0082] Wild-type C. elegans N2 were synchronized and cultured on NGM plates containing E. coli OP50 or a 1:1 mixture of Enterococcus faecalis SI-FC-01 and E. coli OP50 at 20°C for 3 days. After developing into adults, gonadal cell apoptosis was detected. Figure 5 As shown, the number of apoptotic gonadal cells was significantly reduced after supplementation with Enterococcus faecalis SI-FC-01 compared with the E. coli OP50 control group.

[0083] 3. Effect of Enterococcus faecalis SI-FC-01 as a food supplement on the movement of Caenorhabditis elegans.

[0084] Wild-type C. elegans N2 cells were synchronized and cultured on NGM plates containing OP50 or a 1:1 ratio of Enterococcus faecalis SI-FC-01 to Escherichia coli OP50 at 20°C for 36 hours. The worms were then plated in 96-well plates and their motility was monitored for 10 hours using a small animal motility analyzer (MKT100-W Microtracker). Figure 6 As shown, during the larval stage (L2-L3), supplementation with Enterococcus faecalis SI-FC-01 weakened its motility compared with the E. coli OP50 control group.

[0085] Example 4:

[0086] Effects of Enterococcus faecalis SI-FC-01 on lipofuscin in Caenorhabditis elegans.

[0087] Wild-type C. elegans N2 were synchronized at 20°C and cultured on NGM plates containing OP50 for 40 h. They were then transferred to bacterial plates containing 50 μg / ml 5-fluorouracil and grown for 8 days. The nematodes were photographed using a fluorescence microscope and their fluorescence intensity was measured using Image J. The relative fluorescence intensity is shown in Figure 2. Figure 7 As shown in the results, compared to the E. coli OP50 control group, the lipofuscin content in nematodes supplemented with Enterococcus faecalis SI-FC-01 decreased by 14.43%. Lipofuscin is a key indicator of aging, and its formation is primarily the result of lipid peroxidation products. Therefore, Enterococcus faecalis SI-FC-01 may enhance the antioxidant capacity of nematodes.

[0088] Example 5:

[0089] Enterococcus faecalis SI-FC-011 exerts neuroprotective effects on Caenorhabditis elegans.

[0090] 1. Protective effect of Enterococcus faecalis SI-FC-01 on dopamine neurons under Mn pollution.

[0091] L1 stage Caenorhabditis elegans were washed and exposed to 0mM, 5mM, 25mM, and 50mM MnCl2 solutions for 30 minutes. The supernatant was removed by centrifugation, and the cells were washed three times with ddH2O. Then, Escherichia coli OP50 or a 1:1 mixture of Enterococcus faecalis SI-FC-01 and Escherichia coli OP50 was used to feed the cells for 72 hours. Dopamine neurons were observed under a microscope and quantified using Image J software. The results showed that the expression of dopamine neurons in nematodes caused by MnCl2 exposure in the L1 stage was reduced, and feeding with Enterococcus faecalis SI-FC-01 could repair the MnCl2-induced decrease in GFP expression of dopamine neurotransmitters. In addition, MnCl2 also damages the structure of dopamine neurons. The fracture ratio of the test nematodes was counted and it was found that feeding with Enterococcus faecalis SI-FC-01 could restore the damage to dopamine neurons. (e.g. Figure 13 shown)

[0092] 2. The protective effect of Enterococcus faecalis SI-FC-01 on dopamine neurons under PFOS contamination.

[0093] In a 24-well plate, synchronized L1-stage neural nematodes were exposed to 0μM, 0.1μM, 1μM, and 10μM PFOS solutions for 72 hours, supplemented or not with Enterococcus faecalis SI-FC-01. The results showed that PFOS concentrations exceeding 1μM damaged the fluorescence intensity of dopamine neurotransmitters, while Enterococcus faecalis SI-FC-01 could restore this damage. In addition, Enterococcus faecalis SI-FC-01 could also restore the damage to stimulus perception caused by PFOS. (e.g. Figure 14 shown)

[0094] 3. Effect of Enterococcus faecalis SI-FC-01 on the Caenorhabditis elegans Parkinson's disease (PD) model.

[0095] A Parkinson's disease model was constructed by exposing the BZ555 nematode strain to 6-hydroxydopamine (6-OHDA). The L3 larvae (cultured for 40 hours) were rinsed and transferred to a solution containing 10mM ascorbic acid and 50mM (6-OHDA) at a ratio of 1:1. The worm-containing mixture was cultured in a 20°C incubator and shaken every 20 minutes. After incubation for 1 hour, it was washed three times with M9 buffer. The nematodes were placed on a culture plate containing 5-FU and fed with or without SI-FC-01 for 72 hours. Finally, the nematodes were anesthetized and photographed under a microscope, and the fluorescent signals of the obtained images were analyzed using Image J. The results showed that culture of Enterococcus faecalis SI-FC-01 can enhance the activity of dopamine neurons and restore 6-OHDA-induced neuronal damage. (As shown in Figure 2). Figure 15 shown)

[0096] 4. Effects of Enterococcus faecalis SI-FC-01 on Huntington's disease (HD) in Caenorhabditis elegans.

[0097] The AM140 strain is generally used as a nematode model for Huntington's disease. L3 larvae (cultured for 40 hours) are transferred to experimental plates with or without SI-FC-01. AM140 nematodes are collected on the 4th and 8th days. After the nematodes are anesthetized, the aggregation of PolyQ protein is observed using a Leica fluorescence microscope and quantified using Image J software. The results showed that on the 4th and 8th days, supplementation with Enterococcus faecalis SI-FC-01 significantly reduced the age-related accumulation of PolyQ in the body wall muscles of nematodes. (e.g. Figure 16 shown)

[0098] The results of the above examples show that Enterococcus faecalis SI-FC-01 can extend the natural lifespan of Caenorhabditis elegans and enhance its neuroprotective effects, indicating that Enterococcus faecalis SI-FC-01 can delay the aging process while preventing the occurrence of neurodegenerative diseases.

[0099] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the various embodiments of the present invention.

Claims

1. An Enterococcus faecalis SI-FC-01 with anti-aging and neuroprotective effects, characterized in that: The deposit number is CCTCC NO: M 2024091.

2. Use of the Enterococcus faecalis SI-FC-01 according to claim 1 in the preparation of a drug for anti-aging and / or neuroprotection in Caenorhabditis elegans.

3. A bacterial agent, characterized in that Containing the Enterococcus faecalis SI-FC-01 according to claim 1 or its fermentation supernatant or lysate.

4. The use of the bacterial agent according to claim 3 in any of the following: (1) Application in the preparation of anti-aging products; (2) Application in the preparation of products with extended lifespan; (3) Application in the preparation of antioxidant products; (4) Application in the preparation of products that reduce lipofuscin content; (5) Application in the preparation of neuroprotective products; (6) Application in the preparation of antibacterial products.

5. The use according to claim 4, characterized in that In (1) to (5), the product is a health product, a medicine, a feed or an additive thereof.

6. The use according to claim 4, characterized in that In (1) to (5), the product is in the form of liquid, jelly, stick, powder, tablet, granule or capsule.

7. The use according to claim 5, characterized in that The product is a medicine, which also includes a pharmaceutically acceptable carrier.

8. The use according to claim 7, characterized in that The pharmaceutically acceptable carrier is selected from one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.

9. The use according to claim 5, characterized in that The drug is prepared into a pharmaceutically acceptable dosage form.

10. A method for delaying aging and / or protecting neurons in Caenorhabditis elegans, characterized in that: The following steps are involved: The Enterococcus faecalis SI-FC-01 bacterial solution according to claim 1 is added to the culture medium as a food supplement for Caenorhabditis elegans.

Images